A Phase 1, First-in-human, Randomized, Double-blind Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Immunogenicity of 9MW3811 in Healthy Adult Participants
Latest Information Update: 15 Jun 2023
At a glance
- Drugs 9MW 3811 (Primary)
- Indications Pulmonary fibrosis; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Mabwell (Shanghai) Bioscience
- 12 Jun 2023 Status changed from not yet recruiting to recruiting.
- 28 Feb 2023 New trial record
- 27 Feb 2023 According to Mabwell media release, the company has received the official approval by the Australian Therapeutic Goods Administration (TGA) to conduct clinical trials.